Gibson Christopher's Form 4/A amendment
AmendedRecursion Pharmaceuticals, Inc. (RXRX) · filed Jul 12, 2024
- Accession no.
- 0001601830-24-000102
- Filed
- Jul 12, 2024
- Trade date
- Jun 5, 2024
- Filing delay
- 37 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Jun 7, 2024
This filing lists 1 non-derivative transaction and 1 derivative transaction. It carries over 3 transactions from the original filing that it did not restate. Open-market sales total $871.0K. It was filed 37 days after the trade.
This amendment restates part of 0001601830-24-000077 (filed Jun 7, 2024). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Class A Common Stock | CConversionAcquired | +100,000 | $0.00 | $0 | 908,738 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Class A Common Stock | CConversionDisposed | −100,000 | $0.00 | $0 | 6,326,700 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001601830-24-000077 (filed Jun 7, 2024).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Class A Common Stock | GGiftDisposed | −25,000 | $0.00 | $0 | 808,738 | Direct | |
| Jun 5, 2024 | Class A Common Stock | SSaleDisposed | −50,000 | $8.42 | −$421,000 | 758,738 | Direct | |
| Jun 6, 2024 | Class A Common Stock | SSaleDisposed | −50,000 | $9.00 | −$450,000 | 708,738 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a disposition of shares by the Reporting Person.
- F2
This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 27, 2023.
- F3
This amendment corrects the amount of shares converted from Class B Common Stock to Class A Common Stock from 25,000 to 100,000 shares.
- F4
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.